Listed

Opus Genetics, Inc.: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 2, 2018 and accepted by EDGAR at Nov 2, 2018, 16:20 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-07-01 to 2018-09-30$2.9mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$10.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-07-01 to 2018-09-30−$4.7mus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$15.6mus-gaap:OperatingIncomeLoss
Net income3 months2018-07-01 to 2018-09-30−$5.3mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$11.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30−$0.17us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$0.35us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-01-01 to 2018-09-30−$14.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-09-30$4.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$13.7mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$13.9mus-gaap:Assets
Total liabilitiesAt period end2018-09-30$7.5mus-gaap:Liabilities
Shareholders' equityAt period end2018-09-30$6.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-18-042255. Last ingested by Listed: Nov 12, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.